Publications
Detailed Information
Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jae Jin | - |
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Yu, Su Jong | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Joh, Yo-han | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Kwon, Jung Hye | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Kim, Noe Kyeong | - |
dc.date.accessioned | 2020-04-27T11:46:46Z | - |
dc.date.available | 2020-04-27T11:46:46Z | - |
dc.date.created | 2020-04-08 | - |
dc.date.issued | 2004-07 | - |
dc.identifier.citation | Japanese Journal of Clinical Oncology, Vol.34 No.7, pp.400-404 | - |
dc.identifier.issn | 0368-2811 | - |
dc.identifier.other | 95326 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165572 | - |
dc.description.abstract | Objective: The effectiveness of capecitabine, an oral fluoropyrimidine carbamate, is well documented in previously untreated metastatic colorectal cancer patients (overall response rate: 25%). However, its efficacy in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin (5-FU/LV) has not been determined. This study was performed to evaluate the efficacy and to identify the side-effects of capecitabine in patients with metastatic colorectal cancer showing progression despite 5-FU/LV-based combination chemotherapy. Methods: Fifty-one metastatic colorectal cancer patients who showed progressive disease in 5-FU/LV-containing regimens (median: two regimes) were treated with capecitabine 1250 mg/m(2) twice daily (days 1-14 repeated every 3 weeks). Results: Only one partial response was observed (response rate: 2%). Twenty-seven patients (53%) showed stable disease after two cycles. The median time to disease progression of either a partial response or stable disease was 3.4 months. Hand-foot syndrome was the main toxicity of capecitabine and occurred in 35% of cases (grade 3 or 4 in 6%). The median number of cycles administered was two and the relative dose intensity of capecitabine was 80%. Conclusion: The response rate to capecitabine was low in metastatic colorectal cancers that were refractory to 5-FU/LV-containing chemotherapy. However, disease stabilization was seen in a significant number of patients. | - |
dc.language | 영어 | - |
dc.publisher | Oxford University Press | - |
dc.title | Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.1093/jjco/hyh068 | - |
dc.citation.journaltitle | Japanese Journal of Clinical Oncology | - |
dc.identifier.wosid | 000224504300005 | - |
dc.identifier.scopusid | 2-s2.0-6044243224 | - |
dc.citation.endpage | 404 | - |
dc.citation.number | 7 | - |
dc.citation.startpage | 400 | - |
dc.citation.volume | 34 | - |
dc.identifier.sci | 000224504300005 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.contributor.affiliatedAuthor | Kim, Noe Kyeong | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | ORAL FLUOROPYRIMIDINE CARBAMATE | - |
dc.subject.keywordPlus | FLUOROURACIL PLUS LEUCOVORIN | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | CONTINUOUS-INFUSION | - |
dc.subject.keywordPlus | SUPPORTIVE CARE | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | MODULATION | - |
dc.subject.keywordPlus | IRINOTECAN | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | TOXICITY | - |
dc.subject.keywordAuthor | capecitabine | - |
dc.subject.keywordAuthor | metastatic colorectal | - |
dc.subject.keywordAuthor | cancer | - |
dc.subject.keywordAuthor | second-line chemotherapy | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.